|
rs1058172
|
CYP2D6;NDUFA6-DT
|
Major Depressive Disorder
|
|
0.700 |
GeneticVariation |
GWASCAT |
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
|
24528284 |
2014 |
|
rs1058172
|
CYP2D6;NDUFA6-DT
|
response to SSRI
|
|
0.700 |
GeneticVariation |
GWASCAT |
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
|
24528284 |
2014 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
response to SSRI
|
|
0.700 |
GeneticVariation |
GWASCAT |
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
|
24528284 |
2014 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Major Depressive Disorder
|
|
0.700 |
GeneticVariation |
GWASCAT |
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
|
24528284 |
2014 |
|
rs1135840
|
CYP2D6;NDUFA6-DT
|
CYP2D6 polymorphism
|
|
0.030 |
GeneticVariation |
BEFREE |
The effects of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine on dopamine formation from p-tyramine, mediated by cytochrome P450 (CYP) 2D6.2 (Arg296Cys, Ser486Thr) and CYP2D6.10 (Pro34Ser, Ser486Thr), were compared with their effects on CYP2D6.1 (wild type)-mediated dopamine formation, to investigate the influence of a CYP2D6 polymorphism on neuroactive amine metabolism in the brain.
|
31804922 |
2019 |
|
rs1135840
|
CYP2D6;NDUFA6-DT
|
CYP2D6 polymorphism
|
|
0.030 |
GeneticVariation |
BEFREE |
The inhibitory effects of steroid hormones, including glucocorticoids such as cortisol, and related compounds on dopamine formation from p-tyramine, catalyzed by cytochrome P450 (CYP) 2D6.2 (Arg296Cys, Ser486Thr) and CYP2D6.10 (Pro34Ser, Ser486Thr) were compared with the effects of those catalyzed by CYP2D6.1 (wild type), to investigate the effect of a CYP2D6 polymorphism on neuroactive amine metabolism in the brain.
|
28347660 |
2017 |
|
rs1135840
|
CYP2D6;NDUFA6-DT
|
CYP2D6 polymorphism
|
|
0.030 |
GeneticVariation |
BEFREE |
The inhibitory effects of antidepressants, such as imipramine, desipramine, and fluvoxamine, on dopamine formation from p-tyramine catalyzed by cytochrome P450 (CYP) 2D6.2 (Arg296Cys, Ser486Thr) and CYP2D6.10 (Pro34Ser, Ser486Thr), were compared with those on dopamine formation catalyzed by CYP2D6.1 (wild type), to investigate the effect of a CYP2D6 polymorphism on neuroactive amine metabolism in the brain.
|
29602316 |
2018 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation |
BEFREE |
Results indicate that C100T and high serum cholesterol are risk factors of ineffective endoxifen levels in Taiwanese breast cancer patients.
|
31195002 |
2019 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation |
BEFREE |
Results indicate that C100T and high serum cholesterol are risk factors of ineffective endoxifen levels in Taiwanese breast cancer patients.
|
31195002 |
2019 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation |
BEFREE |
The purpose of the study was to determine the association between CYP2D6*10 (c.100C>T) genotype and attainment of the plasma steady-state Z-END minimal threshold concentration (MTC) in Indonesian women with breast cancer.
|
30843495 |
2019 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation |
BEFREE |
The purpose of the study was to determine the association between CYP2D6*10 (c.100C>T) genotype and attainment of the plasma steady-state Z-END minimal threshold concentration (MTC) in Indonesian women with breast cancer.
|
30843495 |
2019 |
|
rs1080985
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Alzheimer's Disease
|
|
0.020 |
GeneticVariation |
BEFREE |
Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients.
|
22465999 |
2012 |
|
rs1080985
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Alzheimer's Disease
|
|
0.020 |
GeneticVariation |
BEFREE |
The single nucleotide polymorphism rs1080985 in the CYP2D6 gene may influence the clinical efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD).
|
19738170 |
2009 |
|
rs1135840
|
CYP2D6;NDUFA6-DT
|
Intraocular pressure disorder
|
|
0.020 |
GeneticVariation |
BEFREE |
Neither rs16947 (P = 0.339) nor rs1135840 (P = 0.903) genotype was statistically correlated with the IOP-lowering effect of timolol eye drops.
|
20925579 |
2010 |
|
rs1135840
|
CYP2D6;NDUFA6-DT
|
Intraocular pressure disorder
|
|
0.020 |
GeneticVariation |
BEFREE |
According to SNP genotyping in 73 subjects, there was no significant difference of IOP between subjects with different CYP2D6 Arg296Cys (P = 0.308) or Ser486Thr genotypes (P = 0.741).
|
19284319 |
2009 |
|
rs16947
|
CYP2D6;NDUFA6-DT
|
Intraocular pressure disorder
|
|
0.020 |
GeneticVariation |
BEFREE |
Neither rs16947 (P = 0.339) nor rs1135840 (P = 0.903) genotype was statistically correlated with the IOP-lowering effect of timolol eye drops.
|
20925579 |
2010 |
|
rs16947
|
CYP2D6;NDUFA6-DT
|
Glaucoma, Primary Open Angle
|
|
0.020 |
GeneticVariation |
BEFREE |
The rs16947 genotype was significantly associated with occurrence of bradycardia in primary open-angle glaucoma patients (P = 0.021).
|
20925579 |
2010 |
|
rs16947
|
CYP2D6;NDUFA6-DT
|
Intraocular pressure disorder
|
|
0.020 |
GeneticVariation |
BEFREE |
According to SNP genotyping in 73 subjects, there was no significant difference of IOP between subjects with different CYP2D6 Arg296Cys (P = 0.308) or Ser486Thr genotypes (P = 0.741).
|
19284319 |
2009 |
|
rs16947
|
CYP2D6;NDUFA6-DT
|
Glaucoma, Primary Open Angle
|
|
0.020 |
GeneticVariation |
BEFREE |
CYP2D6 SNP Arg296Cys appeared to be correlative with the intersubject variability seen with timolol in POAG subjects.
|
19284319 |
2009 |
|
rs1058172
|
CYP2D6;NDUFA6-DT
|
Malignant Head and Neck Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected an association between HNC and CYP1A1 6310C>T (TT) and CYP2D6 Arg365His (His/His) variant carriers (OR 1.75, P = 0.008 and OR 1.66, P = 0.016, respectively).
|
24449363 |
2014 |
|
rs1058172
|
CYP2D6;NDUFA6-DT
|
Head and Neck Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected an association between HNC and CYP1A1 6310C>T (TT) and CYP2D6 Arg365His (His/His) variant carriers (OR 1.75, P = 0.008 and OR 1.66, P = 0.016, respectively).
|
24449363 |
2014 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Schizophrenia
|
|
0.010 |
GeneticVariation |
BEFREE |
The C100T polymorphism of the CYP2D6 gene and the C163A polymorphism of the CYP1A2 gene may be associated with neuroleptic drug-induced tardive dyskinesia in Chinese patients with schizophrenia.
|
16490169 |
2006 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Coronary Arteriosclerosis
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP2D6 (C2850T, G1846A, C100T) polymorphisms, haplotypes and MDR analysis in predicting coronary artery disease risk in north-west Indian population: A case-control study.
|
29660517 |
2018 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
Essential Hypertension
|
|
0.010 |
GeneticVariation |
BEFREE |
Chinese patients with essential hypertension were treated with the β-blocker metoprolol and followed up for 12 weeks. xTAG® liquid-chip technology was used for CYP2D6 100 C > T and ADRB1 1165G > C genotyping.
|
25823457 |
2015 |
|
rs1065852
|
CYP2D6;NDUFA6-DT;LOC112268294
|
CYP2D6 polymorphism
|
|
0.010 |
GeneticVariation |
BEFREE |
The effects of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine on dopamine formation from p-tyramine, mediated by cytochrome P450 (CYP) 2D6.2 (Arg296Cys, Ser486Thr) and CYP2D6.10 (Pro34Ser, Ser486Thr), were compared with their effects on CYP2D6.1 (wild type)-mediated dopamine formation, to investigate the influence of a CYP2D6 polymorphism on neuroactive amine metabolism in the brain.
|
31804922 |
2019 |